Destiny Pharma (LON:DEST) Receives “House Stock” Rating from Shore Capital

Destiny Pharma (LON:DESTGet Free Report)‘s stock had its “house stock” rating reissued by research analysts at Shore Capital in a report issued on Wednesday, Digital Look reports.

Destiny Pharma Stock Down 7.9 %

Shares of DEST opened at GBX 63.10 ($0.80) on Wednesday. Destiny Pharma has a 52 week low of GBX 25 ($0.32) and a 52 week high of GBX 84 ($1.07). The company has a market capitalization of £60.12 million, a price-to-earnings ratio of -788.75 and a beta of 0.39. The stock’s 50-day moving average price is GBX 71.48 and its 200-day moving average price is GBX 58.95.

About Destiny Pharma

(Get Free Report)

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.

Featured Articles

Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.